Le league tables di costo-efficacia

SummaryThis paper asks the question ‘are cost-effectiveness league tables a good way to provide information to decision makers about the value of new healthcare interventions?’ League tables that rank alternative healthcare intervention based on their incremental cost-effectiveness ratio (ICERs) are seen by economists as a valuable tool to inform decision makers about the allocation of scarce healthcare resources. However, league tables frequently compare ICERs from studies that have computed these ratios using different methods and assumptions including choice of comparator, choice of discount rate, time horizon, and population subgroup. The methodological differences among studies may influence the ranking of the studies and therefore decisions made using the league table. In addition, league tables generally do not include measures of the uncertainty of the cost-effectiveness estimates. In this paper, a reference case approach is proposed for the computation of the incremental cost-effectiveness ratio and an expanded set of measures is proposed for inclusion in the league table. In addition, a central repository for reference case expanded league tables is suggested so that decision makers can use them more effectively and more consistently.

[1]  D B Evans,et al.  Development of WHO guidelines on generalized cost-effectiveness analysis. , 2000, Health economics.

[2]  C. Murray,et al.  Stochastic league tables: communicating cost-effectiveness results to decision-makers. , 2001, Health economics.

[3]  A. Williams.  Economics of coronary artery bypass grafting. , 1985, British medical journal.

[4]  A Harris,et al.  Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries , 2001, Expert review of pharmacoeconomics & outcomes research.

[5]  J. V. van Busschbach,et al.  How to define a basic package of health services for a tax funded or social insurance based health care system? , 2001, European Journal of Health Economics.

[6]  Mohan V. Bala,et al.  The Estimation and Use of Confidence Intervals in Economic Analysis , 1999 .

[7]  M. Drummond,et al.  Some guidelines on the use of cost effectiveness league tables. , 1993, BMJ.

[8]  L. Weinehall,et al.  Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease? , 1999, Health policy.

[9]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  M. Weinstein,et al.  Evaluating the cost-effectiveness of clinical and public health measures. , 1998, Annual review of public health.

[11]  A Gafni,et al.  Opportunity costs and uncertainty in the economic evaluation of health care interventions. , 2002, Health economics.

[12]  D. Purcell,et al.  Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy , 2001, AIDS.

[13]  M. Drummond,et al.  Cost-effectiveness league tables: more harm than good? , 1993, Social science & medicine.

[14]  C. Ballantyne,et al.  Maximizing the cost-effectiveness of lipid-lowering therapy. , 1998, Archives of internal medicine.

[15]  W. Hollingworth,et al.  Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population , 1996, BMJ.

[16]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[17]  C. Bell,et al.  A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  G. Torrance,et al.  Cost-effectiveness of antepartum prevention of Rh immunization. , 1984, Clinics in perinatology.

[19]  B. O'brien,et al.  Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. , 2000, Medical care.

[20]  David R. Holtgrave,et al.  Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. , 2001, AIDS.

[21]  A Briggs,et al.  Using cost effectiveness information , 2000, BMJ : British Medical Journal.